Fasken represented Research Capital Corporation in the offering.Algernon Pharmaceuticals Inc. (“Algernon” or “the Company”), a Canadian clinical stage pharmaceutical development company, completed a rights offering of…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
